Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/32176
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPouwels, Koen B.-
dc.contributor.authorYeğenoğlu, Selen-
dc.contributor.authorMcIntosh, E. David-
dc.contributor.authorÜnal, Serhat-
dc.contributor.authorPostma, Maarten J.-
dc.date.accessioned2023-04-04T11:35:52Z-
dc.date.available2023-04-04T11:35:52Z-
dc.date.issued2016-09-10-
dc.identifier.citationPouwels, K. B. vd. (2016). "Potential cost-effectiveness of RSV vaccination of infants and pregnant women in Turkey: An illustration based on Bursa data". Plos One, 11(9).en_US
dc.identifier.issn1932-6203-
dc.identifier.urihttps://doi.org/10.1371/journal.pone.0163567-
dc.identifier.urihttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0163567-
dc.identifier.urihttp://hdl.handle.net/11452/32176-
dc.description.abstractBackground: Worldwide, respiratory syncytial virus (RSV) is considered to be the most important viral cause of respiratory morbidity and mortality among infants and young children. Although no active vaccine is available on the market yet, there are several active vaccine development programs in various stages. To assess whether one of these vaccines might be a future asset for national immunization programs, modeling the costs and benefits of various vaccination strategies is needed. Objectives: To evaluate the potential cost-effectiveness of RSV vaccination of infants and/or pregnant women in Turkey. Methods: A multicohort static Markov model with cycles of one month was used to compare the costeffectiveness of vaccinated cohorts versus nonvaccinated cohorts. The 2014 Turkish birth cohort was divided by twelve to construct twelve monthly birth cohorts of equal size (111,459 new-borns). Model input was based on clinical data from a multicenter prospective study from Bursa, Turkey, combined with figures from the (inter) national literature and publicly available data from the Turkish Statistical Institute (TUIK). Incremental costeffectiveness ratios (ICERs) were expressed in Turkish Lira (TL) per qualityadjusted life year (QALY) gained. Results Vaccinating infants at 2 and 4 months of age would prevent 145,802 GP visits, 8,201 hospitalizations and 48 deaths during the first year of life, corresponding to a total gain of 1650 QALYs. The discounted ICER was estimated at 51,969 TL (26,220 US $ in 2013) per QALY gained. Vaccinating both pregnant women and infants would prevent more cases, but was less attractive from a pure economic point of view with a discounted ICER of 61,653 TL (31,106 US $ in 2013) per QALY. Vaccinating only during pregnancy would result in fewer cases prevented than infant vaccination and a less favorable ICER. Conclusion: RSV vaccination of infants and/or pregnant women has the potential to be costeffective in Turkey. Although using relatively conservative assumptions, all evaluated strategies remained slightly below the threshold of 3 times the GDP per capita.en_US
dc.language.isoenen_US
dc.publisherPublication Library Scienceen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rightsAtıf Gayri Ticari Türetilemez 4.0 Uluslararasıtr_TR
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectScience & technology - other topicsen_US
dc.subjectRespiratory-syncytial-virusen_US
dc.subjectUnited-statesen_US
dc.subjectHigh-risken_US
dc.subjectInfectionen_US
dc.subjectChildrenen_US
dc.subjectInfluenzaen_US
dc.subjectMortalityen_US
dc.subjectHospitalizationen_US
dc.subjectProphylaxisen_US
dc.subjectFrequencyen_US
dc.titlePotential cost-effectiveness of RSV vaccination of infants and pregnant women in Turkey: An illustration based on Bursa dataen_US
dc.typeArticleen_US
dc.identifier.wos000384329200016tr_TR
dc.identifier.scopus2-s2.0-84992134212tr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Çocuk Enfeksiyon Hastalıkları Anabilim Dalı.tr_TR
dc.identifier.volume11tr_TR
dc.identifier.issue9tr_TR
dc.relation.journalPlos Oneen_US
dc.contributor.buuauthorBozdemir, Şefika Elmas-
dc.contributor.buuauthorÇelebi, Solmaz-
dc.contributor.buuauthorHacımustafaoğlu, Mustafa-
dc.relation.collaborationYurt içitr_TR
dc.relation.collaborationYurt dışıtr_TR
dc.relation.collaborationSanayitr_TR
dc.identifier.pubmed27689356tr_TR
dc.subject.wosMultidisciplinary sciencesen_US
dc.indexed.wosSCIEen_US
dc.indexed.scopusScopusen_US
dc.indexed.pubmedPubMeden_US
dc.wos.quartileQ1en_US
dc.contributor.scopusid36112591400tr_TR
dc.contributor.scopusid7006095295tr_TR
dc.contributor.scopusid6602154166tr_TR
dc.subject.scopusPalivizumab; Bronchiolitis; Human Respiratory Syncytial Virusen_US
dc.subject.emtreeRespiratory syncytial virus vaccineen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeCohort analysisen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeCost effectiveness analysisen_US
dc.subject.emtreeDrug efficacyen_US
dc.subject.emtreeEconomic evaluationen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeGestation perioden_US
dc.subject.emtreeHealth care costen_US
dc.subject.emtreeHealth care utilizationen_US
dc.subject.emtreeHealth programen_US
dc.subject.emtreeHospitalizationen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeHuman respiratory syncytial virusen_US
dc.subject.emtreeImmunizationen_US
dc.subject.emtreeInfanten_US
dc.subject.emtreeMarkov chainen_US
dc.subject.emtreePregnant womanen_US
dc.subject.emtreeProspective studyen_US
dc.subject.emtreeQuality of lifeen_US
dc.subject.emtreeRespiratory syncytial virus infectionen_US
dc.subject.emtreeTurkey (republic)en_US
dc.subject.emtreeVaccinationen_US
Appears in Collections:Scopus
Web of Science

Files in This Item:
File Description SizeFormat 
Bozdemir_vd_2016.pdf1.27 MBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons